1-(2-(2-hydroxy-3-phenoxypropylamino)acetyl)pyrrolidine-2-carbonitrile hydrochloride | 1446719-28-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1-(2-(2-hydroxy-3-phenoxypropylamino)acetyl)pyrrolidine-2-carbonitrile hydrochloride
• 英文别名: 1-(2-(2-Hydroxy-3-phenoxypropylamino)acetyl)pyrrolidine-2-carbonitrile hydrochloride；1-[2-[(2-hydroxy-3-phenoxypropyl)amino]acetyl]pyrrolidine-2-carbonitrile;hydrochloride
• CAS: 1446719-28-3
• 化学式: C₁₆H₂₁N₃O₃*ClH
• 分子量: 339.822
• InChiKey: GAWHSPGWWAVUQP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.95
• 重原子数：
  23
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  85.6
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  1-(2-(2-hydroxy-3-phenoxypropylamino)acetyl)pyrrolidine-2-carbonitrile 在 盐酸 作用下， 以 1,4-二氧六环 、 乙醚 为溶剂， 反应 1.0h， 以89.3%的产率得到1-(2-(2-hydroxy-3-phenoxypropylamino)acetyl)pyrrolidine-2-carbonitrile hydrochloride
  参考文献：
  名称：

  NOVEL DIPEPTIDYL-PEPTIDASE-IV INHIBITORS

  摘要：

  该发明涉及一种具有β受体阻滞剂活性的新型二肽基肽酶IV（DPP-IV）抑制剂，其中包括含有治疗有效量的新型DPP-IV抑制剂的药物组合物，以及治疗医学状况的新型方法。本文所述的新型DPP-IV抑制剂对于治疗神经系统疾病、糖尿病、炎症性疾病如关节炎、肥胖症、骨质疏松症、高血压和青光眼等其他已知的可以使用DPP-IV抑制剂和β受体阻滞剂治疗的疾病具有用处。

  公开号：

  US20130184322A1

文献信息

• Dipeptidyl-peptidase-IV inhibitors for treatment of type 2 diabetes complex with hypertension
  申请人：Yang Catherine

  公开号：US09115082B2

  公开（公告）日：2015-08-25

  The invention comprises novel inhibitors of dipeptidyl peptidase IV (DPP-IV) with beta blocker activity, pharmaceutical compositions comprising therapeutically effective amounts of novel inhibitors of DPP-IV, and novel methods of treating medical conditions are provided. The novel inhibitors of DPP-IV described herein are useful in the treatment of neurological disorders, diabetes, inflammatory disorders such as arthritis, obesity, osteoporosis, hypertension, and glaucoma of such other enumerated conditions as can be treated with inhibitors of DPP-IV and beta blockers.

  本发明涉及一种具有β受体阻滞剂活性的新型二肽基肽酶IV（DPP-IV）抑制剂，包括含有治疗有效量的新型DPP-IV抑制剂的制药组合物，以及治疗医疗状况的新型方法。本文所述的新型DPP-IV抑制剂对于治疗神经系统疾病、糖尿病、炎症性疾病如关节炎、肥胖症、骨质疏松症、高血压和青光眼等可使用DPP-IV抑制剂和β受体阻滞剂治疗的其他列举疾病都是有用的。
• NOVEL DDP-IV INHIBITORS
  申请人：DNJ Pharma Inc.

  公开号：EP2945930A1

  公开（公告）日：2015-11-25
• US9115082B2
  申请人：——

  公开号：US9115082B2

  公开（公告）日：2015-08-25
• [EN] NOVEL DDP-IV INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS DE DDP-IV
  申请人：DNJ PHARMA INC

  公开号：WO2014113750A1

  公开（公告）日：2014-07-24

  The invention comprises novel inhibitors of dipeptidyl peptidase IV (DPP-IV) with beta blocker activity, pharmaceutical compositions comprising therapeutically effective amounts of novel inhibitors of DPP-IV, and novel methods of treating medical conditions are provided. The novel inhibitors of DPP-IV described herein are useful in the treatment of neurological disorders, diabetes, inflammatory disorders such as arthritis, obesity, osteoporosis, hypertension, and glaucoma of such other enumerated conditions as can be treated with inhibitors of DPP-IV and beta blockers.
• NOVEL DIPEPTIDYL-PEPTIDASE-IV INHIBITORS
  申请人：Li Weixing

  公开号：US20130184322A1

  公开（公告）日：2013-07-18

  The invention comprises novel inhibitors of dipeptidyl peptidase IV (DPP-IV) with beta blocker activity, pharmaceutical compositions comprising therapeutically effective amounts of novel inhibitors of DPP-IV, and novel methods of treating medical conditions are provided. The novel inhibitors of DPP-IV described herein are useful in the treatment of neurological disorders, diabetes, inflammatory disorders such as arthritis, obesity, osteoporosis, hypertension, and glaucoma of such other enumerated conditions as can be treated with inhibitors of DPP-IV and beta blockers.

  该发明涉及一种具有β受体阻滞剂活性的新型二肽基肽酶IV（DPP-IV）抑制剂，其中包括含有治疗有效量的新型DPP-IV抑制剂的药物组合物，以及治疗医学状况的新型方法。本文所述的新型DPP-IV抑制剂对于治疗神经系统疾病、糖尿病、炎症性疾病如关节炎、肥胖症、骨质疏松症、高血压和青光眼等其他已知的可以使用DPP-IV抑制剂和β受体阻滞剂治疗的疾病具有用处。